LB Pharmaceuticals Inc develops novel therapies for neuropsychiatric diseases, led by LB-102, an oral investigational small molecule and benzamide antipsychotic candidate for schizophrenia, bipolar depression and adjunctive major depressive disorder. Company news frequently centers on LB-102 clinical data, peer-reviewed publications, medical-conference presentations and trial-program updates across schizophrenia and mood-disorder indications.
Other recurring updates include financial results, capital-raising activity, board and executive appointments, Nasdaq inducement grants and healthcare-conference participation. These announcements frame the company's single-segment biopharmaceutical model around clinical development, financing needs and governance as it advances LB-102.
LB Pharmaceuticals (LBRX) has appointed Susan G. Kozauer, M.D. as Chief Medical Officer, adding extensive neuropsychiatric drug development experience to its leadership team.
Dr. Kozauer has more than two decades of clinical development expertise from early-stage studies through regulatory approval, including leading U.S. and global late-stage development of CAPLYTA across adult and pediatric indications at Intra-Cellular Therapies. She most recently served as Senior Vice President, Head of Clinical Development at Centessa Pharmaceuticals, and previously held roles at Premier Research and IQVIA, after practicing as a psychiatrist focused on treatment resistant depression. LB Pharmaceuticals highlighted her role as the company advances toward topline results from its Phase 3 NOVA-2 schizophrenia trial, expected in the first half of 2027, and as it develops LB-102 across multiple neuropsychiatric indications.
LB Pharmaceuticals (LBRX)/b) will present at several investor events in September 2026, including conferences hosted by Wells Fargo, H.C. Wainwright, and TD Cowen.The company will hold in-person 1x1 meetings at Wells Fargo’s 21st Annual Healthcare Conference on September 9 in Boston, virtual presentations and 1x1 meetings at H.C. Wainwright’s 28th Annual Global Investment Conference on September 14, and a virtual fireside chat during TD Cowen’s 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23. Webcasts and replays will be accessible via the Investors/Events section of LB Pharmaceuticals’ website.
LB Pharmaceuticals (LBRX) appointed Joseph Miller as Chief Financial Officer, bringing more than 20 years of biopharmaceutical finance and operational leadership experience to the company.
The company highlights Miller’s track record in scaling infrastructure and teams to support organizational growth, commercialization and long-term value creation. Management ties his appointment to a “potentially transformative period” as LB Pharmaceuticals approaches pivotal NOVA-2 clinical trial results and continues preparations for the potential launch of LB-102 in schizophrenia.
Miller most recently served as CFO of Aurinia Pharmaceuticals, where he built and scaled finance and operations during the transition from late-stage development to the commercial launch of LUPKYNIS for active lupus nephritis, overseeing revenue growth, profitability and an ex-U.S. licensing and collaboration agreement with Otsuka Pharmaceutical. His prior roles include CFO and senior leadership positions at Avalo Therapeutics, Sucampo Pharmaceuticals, QIAGEN, Eppendorf and KPMG LLP.
LB Pharmaceuticals (Nasdaq: LBRX) reported second quarter 2026 results and a corporate update centered on lead candidate LB-102 for schizophrenia and mood disorders. Enrollment in the pivotal Phase 3 NOVA-2 schizophrenia trial is ahead of plan, with topline data now expected in the first half of 2027, followed by a planned pre-NDA FDA meeting in the second half of 2027. A 52-week open-label safety study (NOVA-3) is enrolling, and the Phase 2 bipolar depression trial ILLUMINATE-1 targets topline data in Q1 2028, with a Phase 2 adjunctive MDD study expected to start in early 2027 and read out in the first half of 2029.
Q2 2026 research and development expenses rose to $44.1 million and general and administrative expenses to $9.8 million, driving a net loss of $51.6 million. As of June 30, 2026, cash, cash equivalents and marketable securities were $327.8 million, excluding net proceeds from a $150.0 million July 2026 private placement, which the company expects will fund operations beyond the second quarter of 2029.
LB Pharmaceuticals (Nasdaq: LBRX) entered a securities purchase agreement for a private placement of 3,577,560 common shares and pre-funded warrants to purchase up to 715,513 additional shares at a purchase price of $34.94 per share (and $34.9399 per pre-funded warrant), for anticipated gross proceeds of about $150 million before expenses.
The financing is expected to close on or about July 30, 2026, subject to customary conditions, and includes several new and existing institutional investors. According to LB Pharmaceuticals, net proceeds will fund pipeline expansion of LB-102 into new indications and support working capital and general corporate purposes. The securities are being issued in a unregistered private placement, and the company agreed to file a registration statement to register the resale of the issued shares and the shares underlying the pre-funded warrants.
LB Pharmaceuticals (Nasdaq: LBRX) reported that, based on updated enrollment projections, it now expects topline results from the pivotal Phase 3 NOVA-2 trial of LB-102 in schizophrenia in the first half of 2027, earlier than its prior guidance of the second half of 2027. A pre-NDA meeting with the FDA is expected to be scheduled in the second half of 2027.
NOVA-2 is a multi-center, randomized, double-blind, placebo-controlled Phase 3 study designed to enroll about 460 patients across 25 U.S. sites. According to LB Pharmaceuticals, faster-than-expected enrollment reflects execution strength and interest in LB-102. The company also states it is well capitalized, with a cash runway into Q2 2029, covering multiple planned readouts, including Phase 2 data in bipolar depression in the first quarter of 2028 and in adjunctive major depressive disorder in the first half of 2029.
LB Pharmaceuticals (Nasdaq: LBRX) granted an equity inducement award to its new Senior Vice President, Clinical Operations, Christopher Zergebel, on July 10, 2026. The award consists of an option to purchase 75,000 shares of common stock, granted outside of but subject to the 2025 Equity Incentive Plan under Nasdaq Listing Rule 5635(c)(4).
The stock option has a 10-year term and an exercise price of $32.95, equal to the closing price on the grant date. It vests over four years: 25% after one year and the remaining shares in equal monthly installments over the following three years, contingent on continuous service.
LB Pharmaceuticals (Nasdaq:LBRX) appointed Christopher Zergebel as Senior Vice President, Clinical Operations. He brings over 25 years of global development operations experience across clinical operations, data management, and project and portfolio management.
He will support LB-102 Phase 3 schizophrenia and Phase 2 bipolar depression trials, plus a planned Phase 2 adjunctive major depressive disorder study.
LB Pharmaceuticals (Nasdaq:LBRX) will participate in two June 2026 investor conferences. Executives present at the Jefferies Global Healthcare Conference on June 4, 2026 at 2:35 p.m. ET and at the H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference on June 16, 2026.
Webcasts and replays will be accessible on the company’s Investors > Events webpage.
LB Pharmaceuticals (Nasdaq:LBRX) reported Q1 2026 results and a clinical and corporate update. The company initiated the pivotal Phase 3 NOVA-2 trial in schizophrenia, Phase 2 ILLUMINATE-1 in bipolar 1 depression, and a 52-week NOVA-3 safety study, and published Phase 2 NOVA-1 data in JAMA Psychiatry.
LB Pharmaceuticals closed a $100 million private placement, with net proceeds of $93.8 million, and plans a Phase 2 adjunctive MDD trial in early 2027. Q1 2026 R&D expenses were $14.6 million and G&A expenses $7.5 million, leading to a $19.1 million net loss. Cash, cash equivalents, and marketable securities totaled $365.6 million, expected to fund operations into Q2 2029.